Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$6.1B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the biotechnology sector, focusing on developing innovative therapies for patients with serious diseases. With a market cap of $6 billion, the company is significant in the health care industry, particularly as it navigates the complexities of drug development and commercialization.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.27

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, exceeding expectations by 50%. The stock reacted positively, gaining 23.48% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for key therapies.
Commitment to maintaining strong financial performance.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Kiniksa prepares to report its Q2-2026 earnings. Investors are eager to see if the company can maintain its recent momentum.

Bull Case

If Kiniksa beats EPS expectations again, it could signal strong operational performance and boost investor confidence in its growth trajectory.

Bear Case

Conversely, if the company misses EPS estimates or provides weak guidance, it may raise concerns about its future prospects and lead to a decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.27

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth is critical for assessing the company's ability to expand its market presence and sustain operations.

R&D Expenditure

N/A

Research and development spending reflects the company's commitment to innovation and future product pipeline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected EPS for Q2-2026?

EPS projections will be crucial for understanding the company's profitability and investor sentiment moving forward.

How much is Kiniksa investing in R&D this quarter?

R&D investment levels will indicate the company's commitment to innovation and its potential for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's ability to innovate and expand its product pipeline, given its recent strong performance.

Supporting Evidence

Kiniksa's recent EPS beat suggests operational strength that may not be fully reflected in current expectations.

The options market is pricing a larger move than historical averages, indicating a potential for significant surprises.

The company's commitment to R&D could lead to breakthroughs that analysts are not fully accounting for.

Key Risk

If R&D expenditures show significant growth, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report is pivotal as it will determine whether Kiniksa can sustain its recent positive momentum or if it will face challenges.

Bull Confirmed If

An EPS of $0.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.20 would raise significant concerns about profitability and future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming strong operational performance.

In-Line / Cautious

A cautious inline report may lead to minimal movement in the stock, as investors await further clarity from management.

Miss

If Kiniksa misses expectations, the stock could drop by around 6.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Details on R&D spending and future pipeline developments.
3Any changes to guidance for the upcoming quarters.
4Insights into market conditions and competitive landscape.
5Management's outlook on profitability and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.27

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, exceeding expectations by 50%. The stock reacted positively, gaining 23.48% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for key therapies.
Commitment to maintaining strong financial performance.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Kiniksa prepares to report its Q2-2026 earnings. Investors are eager to see if the company can maintain its recent momentum.

Bull Case

If Kiniksa beats EPS expectations again, it could signal strong operational performance and boost investor confidence in its growth trajectory.

Bear Case

Conversely, if the company misses EPS estimates or provides weak guidance, it may raise concerns about its future prospects and lead to a decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.27

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth is critical for assessing the company's ability to expand its market presence and sustain operations.

R&D Expenditure

N/A

Research and development spending reflects the company's commitment to innovation and future product pipeline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected EPS for Q2-2026?

EPS projections will be crucial for understanding the company's profitability and investor sentiment moving forward.

How much is Kiniksa investing in R&D this quarter?

R&D investment levels will indicate the company's commitment to innovation and its potential for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's ability to innovate and expand its product pipeline, given its recent strong performance.

Supporting Evidence

Kiniksa's recent EPS beat suggests operational strength that may not be fully reflected in current expectations.

The options market is pricing a larger move than historical averages, indicating a potential for significant surprises.

The company's commitment to R&D could lead to breakthroughs that analysts are not fully accounting for.

Key Risk

If R&D expenditures show significant growth, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report is pivotal as it will determine whether Kiniksa can sustain its recent positive momentum or if it will face challenges.

Bull Confirmed If

An EPS of $0.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.20 would raise significant concerns about profitability and future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming strong operational performance.

In-Line / Cautious

A cautious inline report may lead to minimal movement in the stock, as investors await further clarity from management.

Miss

If Kiniksa misses expectations, the stock could drop by around 6.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Details on R&D spending and future pipeline developments.
3Any changes to guidance for the upcoming quarters.
4Insights into market conditions and competitive landscape.
5Management's outlook on profitability and growth strategies.